{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T14:02:25Z","timestamp":1789221745778,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T00:00:00Z","timestamp":1731283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-024-03043-5","type":"journal-article","created":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T09:58:26Z","timestamp":1731319106000},"page":"284-298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Real-world data on direct oral anticoagulants in BCR::ABL1-negative myeloproliferative neoplasms (MPNs): a multicenter retrospective study on behalf of scientific subcommittee on MPNs for Turkish society of hematology"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7681-4623","authenticated-orcid":false,"given":"Mehmet","family":"Baysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif","family":"Aksoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00fcbra Hilal","family":"Bedir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deniz","family":"\u00d6zmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00fcsem","family":"Pat\u0131r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ufuk","family":"Demirci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samet","family":"Yaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra Narl\u0131","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vildan","family":"G\u00fcrsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esra","family":"Y\u0131ld\u0131zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"G\u00fcven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafiye","family":"\u00c7ift\u00e7iler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y\u0131ld\u0131z","family":"\u0130pek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130brahim Ethem","family":"P\u0131nar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine Eylem","family":"Gen\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Mersin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Can","family":"U\u011fur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Tu\u011fba","family":"Karabulut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fehmi","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130pek Y\u00f6nal","family":"Hindilerden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emine","family":"Gulturk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melda","family":"C\u00f6mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkan","family":"Karaku\u015f","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nergiz","family":"Erkut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abd\u00fclkerim","family":"Y\u0131ld\u0131z","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elif G.","family":"\u00dcmit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Muzaffer","family":"Demir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyhan Diz","family":"K\u00fc\u00e7\u00fckkaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet Emre","family":"E\u015fkazan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,11]]},"reference":[{"issue":"4","key":"3043_CR1","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1182\/blood-2009-08-238956","volume":"115","author":"T Barbui","year":"2010","unstructured":"Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E et al (2010) Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 115(4):778\u2013782","journal-title":"Blood"},{"issue":"5","key":"3043_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.7326\/M17-0028","volume":"168","author":"M Hultcrantz","year":"2018","unstructured":"Hultcrantz M, Bj\u00f6rkholm M, Dickman PW, Landgren O, Derolf \u00c5R, Kristinsson SY et al (2018) Risk for arterial and venous thrombosis in patients with myeloproliferative neoplasms: a population-based cohort study. Ann Intern Med 168(5):317\u2013325","journal-title":"Ann Intern Med"},{"issue":"1","key":"3043_CR3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4274\/tjh.galenos.2021.2021.0607","volume":"39","author":"H Hekimo\u011flu","year":"2022","unstructured":"Hekimo\u011flu H, Toprak SF, S\u00f6zer S (2022) JAK2V617F-positive endothelial cells induce apoptosis and release JAK2V617F-positive microparticles. Turk J Hematol 39(1):13\u201321","journal-title":"Turk J Hematol"},{"issue":"9","key":"3043_CR4","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1038\/leu.2013.163","volume":"27","author":"A Tefferi","year":"2013","unstructured":"Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F et al (2013) Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 27(9):1874\u20131881","journal-title":"Leukemia"},{"key":"3043_CR5","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13045-016-0242-9","volume":"9","author":"A Kaifie","year":"2016","unstructured":"Kaifie A, Kirschner M, Wolf D, Maintz C, Hanel M, Gattermann N et al (2016) Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry. J Hematol Oncol 9:18","journal-title":"J Hematol Oncol"},{"issue":"21","key":"3043_CR6","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood.V116.21.3071.3071","volume":"116","author":"M Hultcrantz","year":"2010","unstructured":"Hultcrantz M, Kristinsson SY, Andersson TML, Eloranta S, Derolf \u00c5R, Landgren O et al (2010) Patterns of survival and causes of death In 9,384 patients with myeloproliferative neoplasms diagnosed in Sweden between 1973 and 2008. Blood 116(21):3071","journal-title":"Blood"},{"issue":"Supplement 1","key":"3043_CR7","doi-asserted-by":"publisher","first-page":"6808","DOI":"10.1182\/blood-2022-170607","volume":"140","author":"O Leiva","year":"2022","unstructured":"Leiva O, How C-J, Brunner AM, Hobbs GS (2022) Trends in all-cause and cardiovascular mortality among patients with myeloproliferative neoplasms: a surveillance, epidemiology, and end results database analysis. Blood 140(Supplement 1):6808\u20136809","journal-title":"Blood"},{"issue":"3","key":"3043_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4274\/tjh.2015.0041","volume":"33","author":"N And\u0131\u00e7","year":"2016","unstructured":"And\u0131\u00e7 N, \u00dcn\u00fcbol M, Ya\u011fc\u0131 E, Akay OM, Yava\u015fo\u011flu \u0130, Kad\u0131k\u00f6yl\u00fc VG et al (2016) Clinical features of 294 Turkish patients with chronic myeloproliferative neoplasms. Turk J Hematol 33(3):187\u2013195","journal-title":"Turk J Hematol"},{"issue":"6","key":"3043_CR9","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1007\/s00277-015-2330-2","volume":"94","author":"JC Hern\u00e1ndez-Boluda","year":"2015","unstructured":"Hern\u00e1ndez-Boluda JC, Arellano-Rodrigo E, Cervantes F, Alvarez-Larr\u00e1n A, G\u00f3mez M, Barba P et al (2015) Oral anticoagulation to prevent thrombosis recurrence in polycythemia vera and essential thrombocythemia. Ann Hematol 94(6):911\u2013918","journal-title":"Ann Hematol"},{"issue":"10","key":"3043_CR10","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/leu.2016.85","volume":"30","author":"V De Stefano","year":"2016","unstructured":"De Stefano V, Ruggeri M, Cervantes F, Alvarez-Larr\u00e1n A, Iurlo A, Randi ML et al (2016) High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia 30(10):2032\u20132038","journal-title":"Leukemia"},{"issue":"4","key":"3043_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s12185-017-2282-5","volume":"106","author":"JC Ianotto","year":"2017","unstructured":"Ianotto JC, Couturier MA, Galinat H, Mottier D, Berthou C, Guillerm G et al (2017) Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms. Int J Hematol 106(4):517\u2013521","journal-title":"Int J Hematol"},{"issue":"1","key":"3043_CR12","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s00277-018-3483-6","volume":"98","author":"K Wille","year":"2019","unstructured":"Wille K, Sadjadian P, Becker T, Kolatzki V, Horstmann A, Fuchs C et al (2019) High risk of recurrent venous thromboembolism in BCR-ABL-negative myeloproliferative neoplasms after termination of anticoagulation. Ann Hematol 98(1):93\u2013100","journal-title":"Ann Hematol"},{"issue":"1","key":"3043_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.mayocp.2017.10.007","volume":"93","author":"DT Janczak","year":"2018","unstructured":"Janczak DT, Mimier MK, McBane RD, Kamath PS, Simmons BS, Bott-Kitslaar DM et al (2018) Rivaroxaban and Apixaban for initial treatment of acute venous thromboembolism of atypical location. Mayo Clin Proc 93(1):40\u201347","journal-title":"Mayo Clin Proc"},{"issue":"10","key":"3043_CR14","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","volume":"20","author":"D Farge","year":"2019","unstructured":"Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A et al (2019) 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 20(10):e566\u2013e581","journal-title":"Lancet Oncol"},{"issue":"7","key":"3043_CR15","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C et al (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347","journal-title":"Lancet Oncol"},{"issue":"5","key":"3043_CR16","doi-asserted-by":"publisher","first-page":"e0197583","DOI":"10.1371\/journal.pone.0197583","volume":"13","author":"RCP Makam","year":"2018","unstructured":"Makam RCP, Hoaglin DC, McManus DD, Wang V, Gore JM, Spencer FA et al (2018) Efficacy and safety of direct oral anticoagulants approved for cardiovascular indications: systematic review and meta-analysis. PLoS ONE 13(5):e0197583","journal-title":"PLoS ONE"},{"issue":"22","key":"3043_CR17","doi-asserted-by":"publisher","first-page":"e026723","DOI":"10.1161\/JAHA.122.026723","volume":"11","author":"AM Navar","year":"2022","unstructured":"Navar AM, Kolkailah AA, Overton R, Shah NP, Rousseau JF, Flaker GC et al (2022) Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020. J Am Heart Assoc 11(22):e026723","journal-title":"J Am Heart Assoc"},{"issue":"4","key":"3043_CR18","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA et al (2021) American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974","journal-title":"Blood Adv"},{"issue":"6","key":"3043_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, Bounameaux H, Doerschug K, Geersing G-J et al (2021) Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160(6):2247\u20132259","journal-title":"Chest"},{"issue":"16","key":"3043_CR20","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1200\/JCO.23.00294","volume":"41","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI et al (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol 41(16):3063\u20133071","journal-title":"J Clin Oncol"},{"issue":"1","key":"3043_CR21","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1182\/blood-2019-129705","volume":"134","author":"KL Schoenbeck","year":"2019","unstructured":"Schoenbeck KL, Salmasi G, Cerejo MC, Cornett PA, Damon LE, Logan AC et al (2019) Direct oral anticoagulant use and outcomes in patients with high and intermediate risk BCR-ABL-negative myeloproliferative neoplasms. Blood 134(1):1165","journal-title":"Blood"},{"issue":"3","key":"3043_CR22","doi-asserted-by":"publisher","first-page":"e79","DOI":"10.1111\/bjh.16485","volume":"189","author":"N Curto-Garcia","year":"2020","unstructured":"Curto-Garcia N, Doyle AJ, Breen KA, McLornan DP, Radia DH, Hunt BJ et al (2020) Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. Br J Haematol 189(3):e79\u2013e81","journal-title":"Br J Haematol"},{"issue":"11","key":"3043_CR23","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41408-021-00566-5","volume":"11","author":"J How","year":"2021","unstructured":"How J, Story C, Ren S, Neuberg D, Rosovsky RP, Hobbs GS et al (2021) Practice patterns and outcomes of direct oral anticoagulant use in myeloproliferative neoplasm patients. Blood Cancer J 11(11):176","journal-title":"Blood Cancer J"},{"issue":"4","key":"3043_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694","journal-title":"J Thromb Haemost"},{"issue":"11","key":"3043_CR25","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1111\/jth.13140","volume":"13","author":"S Kaatz","year":"2015","unstructured":"Kaatz S, Ahmad D, Spyropoulos AC, Schulman S (2015) Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost 13(11):2119\u20132126","journal-title":"J Thromb Haemost"},{"key":"3043_CR26","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 36(7):1703\u201319","DOI":"10.1038\/s41375-022-01613-1"},{"issue":"1","key":"3043_CR27","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1055\/a-1334-3259","volume":"41","author":"A Falanga","year":"2021","unstructured":"Falanga A, Marchetti M, Schieppati F (2021) Prevention and management of thrombosis in BCR\/ABL-negative myeloproliferative neoplasms. Hamostaseologie 41(1):48\u201357","journal-title":"Hamostaseologie"},{"issue":"3","key":"3043_CR28","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1111\/bjh.18322","volume":"199","author":"E Jones","year":"2022","unstructured":"Jones E, Dillon B, Swan D, Thachil J (2022) Practical management of the haemorrhagic complications of myeloproliferative neoplasms. Br J Haematol 199(3):313\u2013321","journal-title":"Br J Haematol"},{"issue":"2","key":"3043_CR29","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1111\/ejh.13721","volume":"108","author":"K Wille","year":"2022","unstructured":"Wille K, Huenerbein K, Jagenberg E, Sadjadian P, Becker T, Kolatzki V et al (2022) Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): a retrospective single-center study of 829 MPN patients. Eur J Haematol 108(2):154\u2013162","journal-title":"Eur J Haematol"},{"issue":"8","key":"3043_CR30","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711\u2013719","journal-title":"N Engl J Med"},{"issue":"8","key":"3043_CR31","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720\u2013728","journal-title":"N Engl J Med"},{"issue":"2","key":"3043_CR32","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1111\/jth.14662","volume":"18","author":"RD McBane 2nd","year":"2020","unstructured":"McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A et al (2020) Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial. J Thromb Haemost 18(2):411\u2013421","journal-title":"J Thromb Haemost"},{"issue":"17","key":"3043_CR33","doi-asserted-by":"publisher","first-page":"6196","DOI":"10.1002\/cam4.3269","volume":"9","author":"S Vadhan-Raj","year":"2020","unstructured":"Vadhan-Raj S, McNamara MG, Venerito M, Riess H, O\u2019Reilly EM, Overman MJ et al (2020) Rivaroxaban thromboprophylaxis in ambulatory patients with pancreatic cancer: results from a pre-specified subgroup analysis of the randomized CASSINI study. Cancer Med 9(17):6196\u20136204","journal-title":"Cancer Med"},{"issue":"9","key":"3043_CR34","doi-asserted-by":"publisher","first-page":"5773","DOI":"10.1007\/s00432-022-04535-8","volume":"149","author":"M Cominacini","year":"2023","unstructured":"Cominacini M, Suardi S, Ferrari G, Ciresa R, Tosi F, De Marchi S et al (2023) DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines. J Cancer Res Clin Oncol 149(9):5773\u20135779","journal-title":"J Cancer Res Clin Oncol"},{"issue":"9","key":"3043_CR35","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1007\/s11912-023-01428-y","volume":"25","author":"M Masini","year":"2023","unstructured":"Masini M, Toma M, Spallarossa P, Porto I, Ameri P (2023) Direct oral anticoagulants for cancer-associated venous thromboembolism. Curr Oncol Rep 25(9):979\u2013987","journal-title":"Curr Oncol Rep"},{"key":"3043_CR36","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.tru.2021.100081","volume":"5","author":"S Kelliher","year":"2021","unstructured":"Kelliher S, Falanga A (2021) Thrombosis in myeloproliferative neoplasms: a clinical and pathophysiological perspective. Thrombosis Update 5:100081","journal-title":"Thrombosis Update"},{"issue":"1","key":"3043_CR37","doi-asserted-by":"publisher","first-page":"e12657","DOI":"10.1002\/rth2.12657","volume":"6","author":"T Barbui","year":"2022","unstructured":"Barbui T, Carobbio A, De Stefano V (2022) Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment. Res Pract Thromb Haemost 6(1):e12657","journal-title":"Res Pract Thromb Haemost"},{"issue":"6","key":"3043_CR38","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1055\/s-0039-1693477","volume":"45","author":"DR Arachchillage","year":"2019","unstructured":"Arachchillage DR, Laffan M (2019) Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms. Semin Thromb Hemost 45(6):604\u2013611","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"3043_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41408-019-0225-5","volume":"9","author":"T Barbui","year":"2019","unstructured":"Barbui T, De Stefano V, Falanga A, Finazzi G, Martinelli I, Rodeghiero F et al (2019) Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: a consensus-based position paper. Blood Cancer J 9(8):61","journal-title":"Blood Cancer J"},{"key":"3043_CR40","doi-asserted-by":"publisher","first-page":"107602962210979","DOI":"10.1177\/10760296221097969","volume":"28","author":"L Papageorgiou","year":"2022","unstructured":"Papageorgiou L, Elalamy I, Vandreden P, Gerotziafas GT (2022) Thrombotic and hemorrhagic issues associated with myeloproliferative neoplasms. Clin Appl Thromb Hemost 28:10760296221097968","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"3043_CR41","doi-asserted-by":"publisher","first-page":"100060","DOI":"10.1016\/j.rpth.2023.100060","volume":"7","author":"A Guy","year":"2023","unstructured":"Guy A, Helzy K, Mansier O, Bordet JC, Riviere E, Fiore M et al (2023) Platelet function studies in myeloproliferative neoplasms patients with Calreticulin or JAK2 (V617F) mutation. Res Pract Thromb Haemost 7(2):100060","journal-title":"Res Pract Thromb Haemost"},{"issue":"13","key":"3043_CR42","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.1182\/blood-2013-03-460154","volume":"122","author":"T Barbui","year":"2013","unstructured":"Barbui T, Finazzi G, Falanga A (2013) Myeloproliferative neoplasms and thrombosis. Blood 122(13):2176\u20132184","journal-title":"Blood"},{"key":"3043_CR43","first-page":"33","volume":"225","author":"AS Kim","year":"2020","unstructured":"Kim AS, Khorana AA, McCrae KR (2020) Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res J Lab Clin Med 225:33\u201353","journal-title":"Transl Res J Lab Clin Med"},{"issue":"10","key":"3043_CR44","doi-asserted-by":"publisher","first-page":"8539","DOI":"10.1007\/s00520-022-07160-w","volume":"30","author":"K Dickson","year":"2022","unstructured":"Dickson K, Koom-Dadzie K, Brito-Dellan N, Escalante C (2022) Risks, diagnosis, and management of recurrent cancer-associated thrombosis (CAT): a narrative review. Support Care Cancer 30(10):8539\u20138545","journal-title":"Support Care Cancer"},{"issue":"5","key":"3043_CR45","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1111\/bjh.18276","volume":"198","author":"KM Sanfilippo","year":"2022","unstructured":"Sanfilippo KM, Moik F, Candeloro M, Ay C, Di Nisio M, Lee AYY (2022) Unanswered questions in cancer-associated thrombosis. Br J Haematol 198(5):812\u2013825","journal-title":"Br J Haematol"},{"key":"3043_CR46","doi-asserted-by":"crossref","unstructured":"Castelli R, Berzuini A, Manetti R, Delitala AP, Castro D, Sanna G et al (2024) ADAMTS13, von willebrand factor, platelet microparticles, factor VIII, and impact of somatic mutations in the pathogenesis of splanchnic vein thrombosis associated with BCR-ABL-negative myeloproliferative neoplasms. Life (Basel) 14(4)","DOI":"10.3390\/life14040486"},{"issue":"6s","key":"3043_CR47","first-page":"6s31","volume":"45","author":"M Sebuhyan","year":"2020","unstructured":"Sebuhyan M, Crichi B, Abdallah NA, Bonnet C, Deville L, Marjanovic Z et al (2020) Drug-drug interaction (DDI) with direct oral anticoagulant (DOAC) in patients with cancer. Journal de Medecine Vasculaire. 45(6s):6s31\u20136s8","journal-title":"Journal de Medecine Vasculaire."},{"key":"3043_CR48","doi-asserted-by":"crossref","unstructured":"Raymond J, Imbert L, Cousin T, Duflot T, Varin R, Wils J et al (2021) Pharmacogenetics of direct oral anticoagulants: a systematic review. J Personal Med 11(1)","DOI":"10.3390\/jpm11010037"},{"issue":"2","key":"3043_CR49","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/cpt.2649","volume":"112","author":"J Terrier","year":"2022","unstructured":"Terrier J, Gaspar F, Guidi M, Fontana P, Daali Y, Csajka C et al (2022) Population pharmacokinetic models for direct oral anticoagulants: a systematic review and clinical appraisal using exposure simulation. Clin Pharmacol Ther 112(2):353\u2013363","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3043_CR50","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/17474086.2023.2174515","volume":"16","author":"M Baysal","year":"2023","unstructured":"Baysal M, Bayrak M, E\u015fkazan AE (2023) Current evidence on the use of direct oral anticoagulants in patients with myeloproliferative neoplasm: a systematic review. Expert Rev Hematol 16(2):131\u2013140","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"3043_CR51","doi-asserted-by":"publisher","first-page":"2989","DOI":"10.1038\/s41375-021-01279-1","volume":"35","author":"T Barbui","year":"2021","unstructured":"Barbui T, De Stefano V, Carobbio A, Iurlo A, Alvarez-Larran A, Cuevas B et al (2021) Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. Leukemia 35(10):2989\u20132993","journal-title":"Leukemia"},{"issue":"8","key":"3043_CR52","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1007\/s00277-020-04350-6","volume":"100","author":"K Huenerbein","year":"2021","unstructured":"Huenerbein K, Sadjadian P, Becker T, Kolatzki V, Deventer E, Engelhardt C et al (2021) Direct oral anticoagulants (DOAC) for prevention of recurrent arterial or venous thromboembolic events (ATE\/VTE) in myeloproliferative neoplasms. Ann Hematol 100(8):2015\u20132022","journal-title":"Ann Hematol"},{"issue":"12","key":"3043_CR53","doi-asserted-by":"publisher","first-page":"E329","DOI":"10.1002\/ajh.25990","volume":"95","author":"A Serrao","year":"2020","unstructured":"Serrao A, Breccia M, Napolitano M, Fiori L, Santoro M, Scalzulli E et al (2020) A multicenter real-life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph-negative myeloproliferative neoplasms. Am J Hematol 95(12):E329\u2013E332","journal-title":"Am J Hematol"},{"issue":"6","key":"3043_CR54","doi-asserted-by":"publisher","first-page":"e12574","DOI":"10.1002\/rth2.12574","volume":"5","author":"K Fedorov","year":"2021","unstructured":"Fedorov K, Goel S, Kushnir M, Billett HH (2021) Thrombosis in myeloproliferative neoplasms: treatment outcomes of direct oral anticoagulants and vitamin K antagonists. Res Pract Thromb Haemost 5(6):e12574","journal-title":"Res Pract Thromb Haemost"},{"issue":"Supplement 1","key":"3043_CR55","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1182\/blood-2023-187139","volume":"142","author":"F Cavalca","year":"2023","unstructured":"Cavalca F, Civettini I, Bonfanti S, Gambacorti-Passerini C, Elli EM (2023) Oral anticoagulant therapy in patients with philadelphia-negative myeloproliferative neoplasms: a real-life comparison between Vitamin K antagonists and direct oral anticoagulants. Blood 142(Supplement 1):1838","journal-title":"Blood"},{"issue":"2","key":"3043_CR56","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/S0950-3536(87)80013-6","volume":"1","author":"JA Copplestone","year":"1987","unstructured":"Copplestone JA (1987) Bleeding and coagulation disorders in the elderly. Baillieres Clin Haematol 1(2):559\u2013580","journal-title":"Baillieres Clin Haematol"},{"issue":"8","key":"3043_CR57","doi-asserted-by":"publisher","first-page":"854","DOI":"10.3390\/cells8080854","volume":"8","author":"F Perner","year":"2019","unstructured":"Perner F, Perner C, Ernst T, Heidel FH (2019) Roles of JAK2 in aging, inflammation, hematopoiesis and malignant transformation. Cells 8(8):854","journal-title":"Cells"},{"issue":"10","key":"3043_CR58","doi-asserted-by":"publisher","first-page":"e262","DOI":"10.1161\/ATVBAHA.120.314760","volume":"40","author":"S Matsuura","year":"2020","unstructured":"Matsuura S, Thompson CR, Belghasem ME, Bekendam RH, Piasecki A, Leiva O et al (2020) Platelet dysfunction and thrombosis in JAK2V617F mutated primary myelofibrotic mice. Arterioscler Thromb Vasc Biol 40(10):e262\u2013e272","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"3043_CR59","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.thromres.2022.05.015","volume":"216","author":"L Herbreteau","year":"2022","unstructured":"Herbreteau L, Papageorgiou L, Le Clech L, Garcia G, James C, Pan-Petesch B et al (2022) Benefice and pitfall of direct oral anticoagulants in very high-risk myeloproliferative neoplasms. Thromb Res 216:25\u201334","journal-title":"Thromb Res"},{"issue":"5","key":"3043_CR60","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1080\/00325481.2021.1880844","volume":"133","author":"J How","year":"2021","unstructured":"How J, Story C, Connors JM (2021) Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants. Postgrad Med 133(5):508\u2013516","journal-title":"Postgrad Med"},{"issue":"4","key":"3043_CR61","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/bloodadvances.2019001310","volume":"4","author":"L Naymagon","year":"2020","unstructured":"Naymagon L, Tremblay D, Zubizarreta N, Moshier E, Troy K, Schiano T et al (2020) The efficacy and safety of direct oral anticoagulants in noncirrhotic portal vein thrombosis. Blood Adv 4(4):655\u2013666","journal-title":"Blood Adv"},{"key":"3043_CR62","doi-asserted-by":"crossref","unstructured":"Liu A, Naymagon L, Tremblay D (2022) Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment considerations and unmet needs. Cancers (Basel) 15(1)","DOI":"10.3390\/cancers15010011"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-024-03043-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-024-03043-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T19:25:57Z","timestamp":1741289157000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-024-03043-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,11]]},"references-count":62,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,2]]}},"alternative-id":["3043"],"URL":"https:\/\/doi.org\/10.1007\/s11239-024-03043-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,11]]},"assertion":[{"value":"9 September 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflict of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was approved by Health Sciences University Izmir Bozyaka Training and Research Hospital Clinical Research Ethics Committee (21.06.2023\u20132023\/89).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate\/for publication"}}]}}